Altus Pharmaceuticals is a technology company.
Altus Pharmaceuticals has raised $102.0M across 2 funding rounds.
Altus Pharmaceuticals has raised $102.0M in total across 2 funding rounds.
Altus Pharmaceuticals Inc. was a US-based biopharmaceutical company founded in 1992 and headquartered in Waltham, MA, focused on developing enzyme-based therapeutics and drug delivery technologies.[5][6] It is now out of business, having shuttered operations in October 2009 after delisting from public trading and settling debts with Vertex Pharmaceuticals.[5][6] The company participated in SBIR programs but ultimately ceased activities, with no current products or ongoing clinical trials directly attributable to it in recent records.[6]
Note that multiple entities share similar names: a Zambian distributor (Altus Pharmaceuticals Ltd) imports pharmaceuticals and medical supplies to improve community healthcare access[2]; Altus Drug Development creates value-added medicines using patented drug delivery tech for partners[3][4]; and Altus Pharmaceuticals within Provider Network Holdings provides supply chain services for specialty drugs, supporting 1,500+ physicians.[1] This analysis centers on the original Altus Pharmaceuticals Inc. as the primary match for a technology-driven pharma company, given its innovation history.
Altus Pharmaceuticals Inc. was founded in 1992 in Waltham, MA, initially pursuing enzyme therapeutics and advanced drug formulation technologies.[5][6] Key details on founders are not specified in available records, but the company gained traction through government SBIR funding for biotech innovations and public trading status before facing financial challenges.[6] A pivotal moment came in October 2009 when it voluntarily delisted, settled debts via a deal with Vertex Pharmaceuticals, and shut down operations, marking the end of its journey.[6]
These elements set it apart in the competitive enzyme therapeutics space, though its out-of-business status limits ongoing differentiation.[5]
Altus Pharmaceuticals rode the 1990s-2000s biotech boom in enzyme stabilization and targeted drug delivery, addressing challenges in protein therapeutics stability—a key hurdle for biologics before modern platforms like mRNA emerged.[5][6] Timing aligned with rising interest in outsourced R&D via SBIR, influencing early ecosystem funding for similar firms, but market forces like funding droughts contributed to its 2009 closure amid biotech sector volatility.[6] Its shuttering underscores risks in pre-commercial biopharma, paving the way for survivors like Vertex to consolidate assets and advance the field.
With operations ended since 2009, Altus Pharmaceuticals Inc. has no active future; its technologies likely absorbed via partnerships like Vertex, contributing indirectly to modern drug delivery advances.[6] Trends in value-added formulations—seen in active namesakes like Altus Drug Development—suggest enduring demand for such innovations amid $300B+ specialty drug markets.[1][3][4] Its legacy warns of biopharma pitfalls while highlighting how defunct pioneers fuel ecosystem evolution, tying back to its original mission of tech-driven therapeutics.
Altus Pharmaceuticals has raised $102.0M in total across 2 funding rounds.
Altus Pharmaceuticals's investors include Deerfield Management, U.S. Venture Partners.
Altus Pharmaceuticals has raised $102.0M across 2 funding rounds. Most recently, it raised $51.0M Series C in May 2004.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2004 | $51.0M Series C | Deerfield Management, U.S. Venture Partners | |
| Oct 1, 2001 | $51.0M Series B | U.S. Venture Partners |